1. A A F O B

2. AAFOB
Te c h n o l o g y
TechTranfer
BMM
biotecnología
microbiana
marina
Universidad de Valparaíso
Office
Chile

3. AAFOB
Te c h n o l o g y
Marine natural product
Produced and obtained from a marine bacterium by a controled cost-effective
bioprocess
Physical Food Industry
Surface active molecules
Biological Aquaculture 90 % 1,4
million pof tons

4. The only way to meet the increasing demand for fish is through aquaculture
Daniel Cressey, Nature 458, 398-400 (2009

5. Biomass increases and pathogen apparitions

6. AAFOB
Te c h n o l o g y
Aquaculture challenges
Economic loses Food safety
Pathogen outbreaks
+ Green actions +
Avoid antibiotics
New functional diets

7. AAFOB
Te c h n o l o g y
USERS: SALMON FARMS CUSTOMER: FEED INDUSTRY
Billions people
Million tons
Fast growing economic activity 8,8
% of annual growth rate
60 million tonnes in 2010 with a
value of U$ 119 billion
Mayor producer: China with 60 %

8. Funcional Diets

9. AAFOB
Te c h n o l o g y
QUORUM SENSING AND PATHOGENICITY
VIRULENCE VIRULENCE
ACTIVATED INHIBITED
Chemical Signal for Quorum Sensing
AAFOB Inhibitions by AAFOB is selective
without resistence generation
Quorum sensing is involved in fish
pathogens

10. AAFOB
Te c h n o l o g y
COMPETITORS
ANTIBIOTICS VACCINES AAFOB
Specificity   
Resistance X X 
Production cost  X 
Implementation cost  X 
Food safety  
X
Environment
X  
CUSTOMER BENEFITS
•BIOMASS PRODUCTION
•FOOD SAFETY

11. Biosurfactant
Technology
Incorpora1on
of
BS
into
polymeric
matrices:
• BIO-­‐Silicone
urinary
catheters
Physical
and
chemical
proper1es
Advantages:
• Amphiphilic
compounds
• No
bacterial
resistance
• Reduc8on
of
surface
an
interfacial
tension
• Large
scale-­‐produc8on
• Incorpora8on
on
different
matrices.
• Reduce
usage
of
potable
water
Biological
proper1es
• Interference
with
cell-­‐to-­‐cell
communica8on
system
:
Quorum
Sensing
• Inhibi8on
of
virulence
factors
expression
• Immunomodula8on

12. Catheter-­‐associated
Urinary
Tract
Infec8ons
• 27% of total health-care associated
infections.1
• Catheterization increases the infection
risk in a 5%, per day.2
• Bacterial strains resistant to
conventional antibiotic therapies.
• Each CAUTI increase medical care
costs in U$600, per patient.3
• Bacteremia caused by CAUTI increase
medical care costs in U$2800, per
patient.4
1
HELICS,
2005.
2
Garidaldi
RA,
Burke
JP,
Dickman
ML
and
Smith
CB
(1974).
Factors
predisposing
to
bacteriuria
during
indwelling
urethral
catheterisa8on.
The
New
England
Journal
of
Medicine
291:213-­‐219.
3
Jarvis
WR.
Selected
aspects
of
the
socioeconomic
impact
of
nosocomial
infec8ons:
morbidity,
mortality,
cost,
and
preven8on.
Infect
Control
Hosp
Epidemiol.
1996;17(8):552–7
4Tambyah
PA,
Knasinski
V,
Maki
DG.
The
direct
costs
of
nosocomial
catheter-­‐associated
urinary
tract
infec8on
in
the
era
of
managed
care.
Infect
Control
Hosp
Epidemiol.
2002;23(1):27–31

13. AAFOB
Te c h n o l o g y
AAFOB TECH TRANSFER

14. AAFOB
Te c h n o l o g y
Funded by
Scientific validation Chilean Fondef D07I1061
and Patent International PCT Corfo Innova L4
Licences Productive Corfo Innova L4
Comercial
Trade Mark INAPI
Spin off Micro MBtk Biotk Corfo Innova L4
Fondef VIU
Investors seeking to UE and EEUU Corfo GoTo Market
implement production
and distribution
OK
Developing

15. AAFOB
Te c h n o l o g y
Go To Market Barriers
 Natural products
 Local Regulations  Toxicity assays (in vitro and LD50)
 Field assay with AAFOB based diets
 Production  HC Industrial Fermentation is
required
 Distribution  For global market

16. AAFOB
Te c h n o l o g y
Enregy Aquaculture
Industry Biomedicine

17. Marine natural products can support the sustainable growth of an aquaculture safe for people and environmentally friendly
AAFOB
Te c h n o l o g y